{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:46:49Z","timestamp":1792198009054,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41379-022-01074-y","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T07:21:58Z","timestamp":1651562518000},"page":"1212-1219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-7562","authenticated-orcid":false,"given":"Ali","family":"Sakhdari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Class","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-261X","authenticated-orcid":false,"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-7880","authenticated-orcid":false,"given":"Chi Young","family":"Ok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergej N.","family":"Konoplev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop P.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-022-01074-y_bib1","unstructured":"Swerdlow, S. H., Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition. (IARC, 2017)."},{"key":"10.1038\/s41379-022-01074-y_bib2","doi-asserted-by":"crossref","unstructured":"Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454\u20132465 (2012).","DOI":"10.1182\/blood-2012-03-420489"},{"key":"10.1038\/s41379-022-01074-y_bib3","doi-asserted-by":"crossref","unstructured":"Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G. et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364, 2496\u20132506 (2011).","DOI":"10.1056\/NEJMoa1013343"},{"key":"10.1038\/s41379-022-01074-y_bib4","doi-asserted-by":"crossref","unstructured":"Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616\u20133627; quiz 3699 (2013).","DOI":"10.1182\/blood-2013-08-518886"},{"key":"10.1038\/s41379-022-01074-y_bib5","doi-asserted-by":"crossref","unstructured":"Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17, 5\u201319 (2017).","DOI":"10.1038\/nrc.2016.112"},{"key":"10.1038\/s41379-022-01074-y_bib6","doi-asserted-by":"crossref","unstructured":"Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241\u2013247 (2014).","DOI":"10.1038\/leu.2013.336"},{"key":"10.1038\/s41379-022-01074-y_bib7","doi-asserted-by":"crossref","unstructured":"Bejar, R., Levine, R. & Ebert, B. L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 29, 504\u2013515 (2011).","DOI":"10.1200\/JCO.2010.31.1175"},{"key":"10.1038\/s41379-022-01074-y_bib8","doi-asserted-by":"crossref","unstructured":"Bejar, R., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O., Steensma, D. P., Galili, N. et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30, 3376\u20133382 (2012).","DOI":"10.1200\/JCO.2011.40.7379"},{"key":"10.1038\/s41379-022-01074-y_bib9","doi-asserted-by":"crossref","unstructured":"Hosono, N. Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol 24, 885\u2013892 (2019).","DOI":"10.1007\/s10147-019-01462-6"},{"key":"10.1038\/s41379-022-01074-y_bib10","doi-asserted-by":"crossref","unstructured":"Malcovati, L., Papaemmanuil, E., Bowen, D. T., Boultwood, J., Della Porta, M. G., Pascutto, C. et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood 118, 6239\u20136246 (2011).","DOI":"10.1182\/blood-2011-09-377275"},{"key":"10.1038\/s41379-022-01074-y_bib11","doi-asserted-by":"crossref","unstructured":"Garcia-Manero, G., Shan, J., Faderl, S., Cortes, J., Ravandi, F., Borthakur, G. et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22, 538-543 (2008).","DOI":"10.1038\/sj.leu.2405070"},{"key":"10.1038\/s41379-022-01074-y_bib12","doi-asserted-by":"crossref","unstructured":"Xu, F. & Li, X. The role of histone methyltransferase EZH2 in myelodysplastic syndromes. Expert Rev Hematol 5, 177\u2013185 (2012).","DOI":"10.1586\/ehm.12.5"},{"key":"10.1038\/s41379-022-01074-y_bib13","doi-asserted-by":"crossref","unstructured":"Nikoloski, G., Langemeijer, S. M., Kuiper, R. P., Knops, R., Massop, M., Tonnissen, E. R. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42, 665\u2013667 (2010).","DOI":"10.1038\/ng.620"},{"key":"10.1038\/s41379-022-01074-y_bib14","doi-asserted-by":"crossref","unstructured":"Wu, L., Song, L., Xu, L., Chang, C., Xu, F., Wu, D. et al. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. Tumour Biol 37, 4633\u20134640 (2016).","DOI":"10.1007\/s13277-015-4305-2"},{"key":"10.1038\/s41379-022-01074-y_bib15","doi-asserted-by":"crossref","unstructured":"Sashida, G., Harada, H., Matsui, H., Oshima, M., Yui, M., Harada, Y. et al. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat Commun 5, 4177 (2014).","DOI":"10.1038\/ncomms5177"},{"key":"10.1038\/s41379-022-01074-y_bib16","doi-asserted-by":"crossref","unstructured":"Gollner, S., Oellerich, T., Agrawal-Singh, S., Schenk, T., Klein, H. U., Rohde, C. et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nature Medicine 23, 69\u201378 (2017).","DOI":"10.1038\/nm.4247"},{"key":"10.1038\/s41379-022-01074-y_bib17","doi-asserted-by":"crossref","unstructured":"Lambert, M., Alioui, M., Jambon, S., Depauw, S., Van Seuningen, I. & David-Cordonnier, M. H. Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia. Cancers (Basel) 11, 837 (2019).","DOI":"10.3390\/cancers11060837"},{"key":"10.1038\/s41379-022-01074-y_bib18","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhang, M., Sheng, M., Zhang, P., Chen, Z., Xing, W. et al. Therapeutic potential of GSK-J4, a histone demethylase KDM6B\/JMJD3 inhibitor, for acute myeloid leukemia. J Cancer Res Clin Oncol 144, 1065\u20131077 (2018).","DOI":"10.1007\/s00432-018-2631-7"},{"key":"10.1038\/s41379-022-01074-y_bib19","doi-asserted-by":"crossref","unstructured":"Rinke, J., Chase, A., Cross, N. C. P., Hochhaus, A. & Ernst, T. EZH2 in Myeloid Malignancies. Cells 9, 1639 (2020).","DOI":"10.3390\/cells9071639"},{"key":"10.1038\/s41379-022-01074-y_bib20","doi-asserted-by":"crossref","unstructured":"Kanagal\u2010Shamanna, R., Bueso\u2010Ramos, C. E., Barkoh, B., Lu, G., Wang, S., Garcia\u2010Manero, G. et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild\u2010type TP53. Cancer 118, 2879\u20132888 (2012).","DOI":"10.1002\/cncr.26537"},{"key":"10.1038\/s41379-022-01074-y_bib21","unstructured":"ISCN 2016 - An International System for Human Cytogenomic Nomenclature (2016). In: Simons A. McGowan-Jordan J., Schmid M. (ed). (2016)."},{"key":"10.1038\/s41379-022-01074-y_bib22","doi-asserted-by":"crossref","unstructured":"Kanagal-Shamanna, R., Luthra, R., Yin, C. C., Patel, K. P., Takahashi, K., Lu, X. et al. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7, 14251\u201314258 (2016).","DOI":"10.18632\/oncotarget.7350"},{"key":"10.1038\/s41379-022-01074-y_bib23","doi-asserted-by":"crossref","unstructured":"Montalban-Bravo, G., Kanagal-Shamanna, R., Sasaki, K., Patel, K., Ganan-Gomez, I., Jabbour, E. et al. NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3, 922\u2013933 (2019).","DOI":"10.1182\/bloodadvances.2018026989"},{"key":"10.1038\/s41379-022-01074-y_bib24","doi-asserted-by":"crossref","unstructured":"Kanagal-Shamanna, R., Singh, R. R., Routbort, M. J., Patel, K. P., Medeiros, L. J. & Luthra, R. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Review of Molecular Diagnostics 16, 461\u2013472 (2016).","DOI":"10.1586\/14737159.2016.1142374"},{"key":"10.1038\/s41379-022-01074-y_bib25","doi-asserted-by":"crossref","unstructured":"Wu, H., Zeng, H., Dong, A., Li, F., He, H., Senisterra, G. et al. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PLoS One 8, e83737 (2013).","DOI":"10.1371\/journal.pone.0083737"},{"key":"10.1038\/s41379-022-01074-y_bib26","doi-asserted-by":"crossref","unstructured":"Yap, D. B., Chu, J., Berg, T., Schapira, M., Cheng, S. W., Moradian, A. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451\u20132459 (2011).","DOI":"10.1182\/blood-2010-11-321208"},{"key":"10.1038\/s41379-022-01074-y_bib27","doi-asserted-by":"crossref","unstructured":"Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42, 181\u2013185 (2010).","DOI":"10.1038\/ng.518"},{"key":"10.1038\/s41379-022-01074-y_bib28","doi-asserted-by":"crossref","unstructured":"Berg, T., Thoene, S., Yap, D., Wee, T., Schoeler, N., Rosten, P. et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 123, 3914\u20133924 (2014).","DOI":"10.1182\/blood-2012-12-473439"},{"key":"10.1038\/s41379-022-01074-y_bib29","doi-asserted-by":"crossref","unstructured":"Cabrero, M., Wei, Y., Yang, H., Ganan-Gomez, I., Bohannan, Z., Colla, S. et al. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44, 1\u20137 (2016).","DOI":"10.1016\/j.leukres.2016.02.009"},{"key":"10.1038\/s41379-022-01074-y_bib30","doi-asserted-by":"crossref","unstructured":"Shirahata-Adachi, M., Iriyama, C., Tomita, A., Suzuki, Y., Shimada, K. & Kiyoi, H. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome. Leuk Res 63, 90\u201397 (2017).","DOI":"10.1016\/j.leukres.2017.10.015"},{"key":"10.1038\/s41379-022-01074-y_bib31","doi-asserted-by":"crossref","unstructured":"Wang, Y., Hou, N., Cheng, X., Zhang, J., Tan, X., Zhang, C. et al. Ezh2 acts as a tumor suppressor in Kras-driven lung adenocarcinoma. Int J Biol Sci 13, 652\u2013659 (2017).","DOI":"10.7150\/ijbs.19108"},{"key":"10.1038\/s41379-022-01074-y_bib32","doi-asserted-by":"crossref","unstructured":"Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K. et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366, 1090\u20131098 (2012).","DOI":"10.1056\/NEJMoa1106968"},{"key":"10.1038\/s41379-022-01074-y_bib33","doi-asserted-by":"crossref","unstructured":"Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30, 413\u2013421 (2012).","DOI":"10.1038\/nbt.2203"},{"key":"10.1038\/s41379-022-01074-y_bib34","doi-asserted-by":"crossref","unstructured":"Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C. et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 160, 660\u2013672 (2013).","DOI":"10.1111\/bjh.12203"},{"key":"10.1038\/s41379-022-01074-y_bib35","doi-asserted-by":"crossref","unstructured":"Hasegawa, N., Oshima, M., Sashida, G., Matsui, H., Koide, S., Saraya, A. et al. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia 31, 861\u2013871 (2017).","DOI":"10.1038\/leu.2016.268"},{"key":"10.1038\/s41379-022-01074-y_bib36","doi-asserted-by":"crossref","unstructured":"Muto, T., Sashida, G., Oshima, M., Wendt, G. R., Mochizuki-Kashio, M., Nagata, Y. et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 210, 2627\u20132639 (2013).","DOI":"10.1084\/jem.20131144"},{"key":"10.1038\/s41379-022-01074-y_bib37","doi-asserted-by":"crossref","unstructured":"Wang, J., Ai, X., Gale, R. P., Xu, Z., Qin, T., Fang, L. et al. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res 37, 305\u2013311 (2013).","DOI":"10.1016\/j.leukres.2012.10.004"},{"key":"10.1038\/s41379-022-01074-y_bib38","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H. et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180\u2013193 (2012).","DOI":"10.1016\/j.ccr.2012.06.032"},{"key":"10.1038\/s41379-022-01074-y_bib39","doi-asserted-by":"crossref","unstructured":"Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M. J. et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24, 1062\u20131065 (2010).","DOI":"10.1038\/leu.2010.20"},{"key":"10.1038\/s41379-022-01074-y_bib40","doi-asserted-by":"crossref","unstructured":"Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N. et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145, 788\u2013800 (2009).","DOI":"10.1111\/j.1365-2141.2009.07697.x"},{"key":"10.1038\/s41379-022-01074-y_bib41","doi-asserted-by":"crossref","unstructured":"Hosono, N., Makishima, H., Jerez, A., Yoshida, K., Przychodzen, B., McMahon, S. et al. Recurrent genetic defects on chromosome 7q in myeloid neoplasms. Leukemia 28, 1348\u20131351 (2014).","DOI":"10.1038\/leu.2014.25"},{"key":"10.1038\/s41379-022-01074-y_bib42","doi-asserted-by":"crossref","unstructured":"Jerez, A., Sugimoto, Y., Makishima, H., Verma, A., Jankowska, A. M., Przychodzen, B. et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 119, 6109\u20136117 (2012).","DOI":"10.1182\/blood-2011-12-397620"},{"key":"10.1038\/s41379-022-01074-y_bib43","doi-asserted-by":"crossref","unstructured":"Dubois, S., Mareschal, S., Picquenot, J. M., Viailly, P. J., Bohers, E., Cornic, M. et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget 6, 16712\u201316724 (2015).","DOI":"10.18632\/oncotarget.3154"},{"key":"10.1038\/s41379-022-01074-y_bib44","doi-asserted-by":"crossref","unstructured":"Mcgraw, K. L., Nguyen, J., Alali, N., Song, J. M., Sallman, D., Padron, E. et al. EZH2 protein expression is decreased in MDS and MDS\/MPN and correlated with EZH2 mutation status, chromosomal 7 abnormalities and clinical outcome. Blood 128 (2016).","DOI":"10.1182\/blood.V128.22.4305.4305"},{"key":"10.1038\/s41379-022-01074-y_bib45","doi-asserted-by":"crossref","unstructured":"Veitia, R. A., Bottani, S. & Birchler, J. A. Gene dosage effects: nonlinearities, genetic interactions, and dosage compensation. Trends Genet 29, 385\u2013393 (2013).","DOI":"10.1016\/j.tig.2013.04.004"},{"key":"10.1038\/s41379-022-01074-y_bib46","doi-asserted-by":"crossref","unstructured":"Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C., Ramakrishnan, A. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617\u2013630 (2015).","DOI":"10.1016\/j.ccell.2015.04.006"},{"key":"10.1038\/s41379-022-01074-y_bib47","doi-asserted-by":"crossref","unstructured":"Gall Troselj, K., Novak Kujundzic, R. & Ugarkovic, D. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background. Clin Epigenetics 8, 55 (2016).","DOI":"10.1186\/s13148-016-0226-1"},{"key":"10.1038\/s41379-022-01074-y_bib48","doi-asserted-by":"crossref","unstructured":"Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343\u2013349 (2011).","DOI":"10.1038\/nature09784"},{"key":"10.1038\/s41379-022-01074-y_bib49","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Gao, J., Popovic, R., Wolniak, K., Parimi, V., Winter, J. N. et al. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma 56, 2895\u20132901 (2015).","DOI":"10.3109\/10428194.2015.1006220"},{"key":"10.1038\/s41379-022-01074-y_bib50","doi-asserted-by":"crossref","unstructured":"Chase, A., Score, J., Lin, F., Bryant, C., Waghorn, K., Yapp, S. et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia 34, 3206\u20133214 (2020).","DOI":"10.1038\/s41375-020-0816-y"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01074-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01074-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222002769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-022-01074-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:30:33Z","timestamp":1760229033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222002769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0893395222002769"],"URL":"https:\/\/doi.org\/10.1038\/s41379-022-01074-y","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-022-01074-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}